Research Divisions

Endocrinology, Nutrition, Diabetes and Obesity

Group LeaderPrincipal InvestigatorsLocation and ContactMembersHistory of the GroupLines of ResearchNotable PublicationsProjectsPhD ThesesClinical TrialsNews
Dr Elías Delgado
Dr Elías Delgado

Elías Delgado Álvarez

  • Tenured Lecturer. Faculty of Medicine Universidad de Oviedo.
  • HEAD OF THE DIABETES SECTION in the Endocrinology and Nutrition Department of the Hospital Universitario Central de Asturias (HUCA), Oviedo.
  • PRINCIPAL INVESTIGATOR of the Endocrinology, Nutrition, Diabetes and Obesity (ENDO) Research Group and COORDINATOR of ISPA’s Metabolism research division.
  • Vice Dean of the Faculty of Medicine, Universidad de Oviedo.

 

The main lines of research in which I am involved are:

1.- Epidemiology of type 2 diabetes mellitus and all the cardiovascular risk factors. Member of the Scientific Committee for the SED (Spanish Diabetes Society) Di@bet.es Study.

2.- Genetics and epigenetics of type 2 diabetes mellitus.

3.- Treatment of type 1 diabetes mellitus with umbilical cord blood stem cells (“Stem Cell Educator”).

4.- Prevalence and early detection of hydrocarbon metabolism disorders in the population suffering from cardiological pathologies .

5.- Eradication of iodine-deficiency disorders in Asturias.

 

My most significant publications can be found on the academic databases using my Research ID – B-2634-2013, my SCOPUS Author ID – 7102440254, or my ORCID ID – https://orcid.org/0000-0001-6114-9712

My latest publications are listed below:

  • Avogaro A, Delgado E, Lingvay I. When Metformin Is Not Enough: Pros and Cons of SGLT2 and DPP-4 Inhibitors as a Second Line Therapy. Diabetes Metab Res Rev. 2018 Jan 10;
  • Rodriguez-Rodero S, Menendez-Torre E, Fernandez-Bayon G, Morales-Sanchez P, Sanz L, Turienzo E, et al. Altered intragenic DNA methylation of HOOK2 gene in adipose tissue from individuals with obesity and type 2 diabetes. PLoS One. 2017;12(12):e0189153.
  • Riestra Fernandez M, Menendez Torre E, Diaz Cadorniga F, Fernandez Fernandez JC, Delgado Alvarez E. Iodine nutritional status in Asturian schoolchildren. Endocrinol Diabetes Nutr. 2017 Nov;64(9):491–7.
  • Zhao Y, Jiang Z, Delgado E, Li H, Zhou H, Hu W, et al. Platelet-Derived Mitochondria Display Embryonic Stem Cell Markers and Improve Pancreatic Islet β-cell Function in Humans. Stem Cells Transl Med. 2017 Aug;6(8):1684–97.
  • Prevalence, Diagnosis, Treatment, and Control of Hypertension in Spain. Results of the Di@bet.es Study. Rev Esp Cardiol (Engl Ed). 2016 Mar 12. pii: S1885-5857(16)00050-5. doi: 10.1016/j.rec.2015.11.034. [Epub ahead of print] English, Spanish.
  • Moreno M, Moreno-Navarrete JM, Serrano M, Ortega F, Delgado E, Sanchez-Ragnarsson C, et al. Circulating irisin levels are positively associated with metabolic risk factors in sedentary subjects. PLoS ONE. 2015;10(4):e0124100.
  • Delgado E, Perez-Basterrechea M, Suarez-Alvarez B, Zhou H, Revuelta EM, Garcia-Gala JM, et al. Modulation of Autoimmune T-Cell Memory by Stem Cell Educator Therapy: Phase 1/2 Clinical Trial. EBioMedicine [Internet]. 2015; 2(12): 2024-2036
  • Bellido V, Suarez L, Rodriguez MG, Sanchez C, Dieguez M, Riestra M, et al. Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes. Diabetes Care. 2015;38(12):2211-6.

Edelmiro Luis Menéndez Torre

Head of the Endocrinology and Nutrition Department, HUCA

Associate Lecturer in the Department of Medicine, Universidad de Oviedo

Twitter: @Edelangot

 

Jesús María de la Hera Galarza

Manager of the Cardiac Imaging Unit, Cardiology Department, HUCA

 

Sandra Rodríguez Rodero

Doctor of Biochemistry
Clinical Researcher at ISPA-HUCA

Sandra Rodríguez Rodero obtained her Bachelor’s Degree in the Faculty of Biochemistry, Universidad de Oviedo, in 1997. She then completed her PhD thesis in HUCA’s Immunology and Histocompatibility Department, focusing on the innate immunological response to tumours and autoimmune diseases, under the supervision of Professor Carlos López Larrea. She developed further experience in this field as a postdoctoral researcher at the University of Oxford’s Nuffield Department of Medicine (United Kingdom), as part of Professor Sarah Rowland Jones’ research group and in collaboration with Professor Chris O´Callaghan’s Innate Immunology group in the same department, working on the innate immune response in viral infections such as HIV.

She currently works as a clinical researcher in ISPA’s Endocrinology, Nutrition, Diabetes and Obesity unit, led by Dr Elias Delgado Alvarez, her research focusing on identifying the epigenetic mechanisms involved in the development of tumours of endocrine origin, as well as metabolic pathologies (obesity, type 2 diabetes).

Servicio Endocrinología y Nutrición – HUCA. Secretary: Edificio de Consultas Externas, Planta 0- Bloque A

Avenida Hospital Universitario, s/n

33011 – Oviedo, Spain.

Telephone: +34 985108000-Ext: 36329

E-mail: delgadoelias@uniovi.es

Twitter: @endo_ispa

Name Organisation Activity Euraxess classification
Alonso Felgueroso, Carlos SESPA Research/Clinical R1
Ares Blanco, Jessica SESPA Research/Clinical R2
Botas Cervero, Patricia SESPA Research/Clinical R2
de la Hera Galarza, Jesús María SESPA Research/Clinical R2
Delgado Álvarez, Elías Universidad de Oviedo/SESPA Research/Clinical/Teaching R4
Díaz Naya, Lucía SESPA Research/Clinical R2
Diéguez Felechosa, Marta SESPA Research/Clinical R2
González Martínez, Silvia SESPA Research/Clinical R2
Gutiérrez Buey, Gala SESPA Research/Clinical R2
Lambert Goitia, Carmen FINBA Research R2
Manjón Miguélez, Laura SESPA Research/Clinical R2
Martínez Faedo, Ceferino SESPA Research/Clinical R2
Menéndez Torre, Edelmiro SESPA/Universidad de Oviedo Research/Clinical/Teaching R2
Morales Sánchez, Paula FINBA Research R1
Pujante Alarcón, Pedro SESPA Research/Clinical R2
Riestra Fernández, María SESPA Research/Clinical R2
Rodríguez Escobedo, Raúl SESPA Research/Clinical R2
Rodríguez Rodero, Sandra CSIC Research R2
Sánchez Ragnarsson, Cecilia SESPA Research/Clinical R2
Suárez Gutiérrez, Lorena SESPA Research/Clinical R2
Valdés Gallego, Nuria SESPA Research/Clinical R3
Villazón González, Francisco SESPA Research/Clinical/Teaching R2
Villa Fernández, Elsa Universidad de Oviedo Research No classification

Our research group was established within the Endocrinology and Nutrition Department of the Hospital Universitario Central de Asturias (HUCA).

For some time, we had felt the need to conduct fieldwork beyond the confines of the hospital, in order to meet two main objectives. The first of these was to establish the real prevalence and incidence of hydrocarbon metabolism disorders in our region and, in collaboration with primary care doctors, use these results to produce early diagnosis and prevention strategies for at-risk individuals which were able to improve the health of the population. The second objective was to gain biological samples from these cohorts (developing a collection of serum samples and a gene library), in order to conduct more in-depth basic research and facilitate translational research.

With these objectives in mind, we are working on the following lines of research:

The Epidemiology of Diabetes in Asturias

“ASTURIAS Study”: The research element of our work on diabetes began in 1998 when, with support from a Health Research Fund (FIS) grant (FIS-98/0462: “The Prevalence of Non-insulin-dependent Diabetes in the Asturian Population Aged over 30 Years), Dr Patricia Botas conducted a representative sampling exercise on the Asturian population (1089 people) which enabled us to estimate the prevalence of type 2 diabetes mellitus (DM2) and other cardiovascular risk factors in the region of Asturias. After this initial evaluation, which established the baseline parameters for this population, we conducted two further studies on it: one led by Dr Sergio Valdés in 2010 and the other by Dr Cecilia Sánchez. The most significant information provided by these studies included the incidence of DM2 and the mortality associated with hydrocarbon metabolism disorders in Asturias. Both studies were carried out with the support of the Consejería de Salud del Principado de Asturias. We are currently completing the fieldwork for a new analytical study of the population sampled in 1998, after 15 years of monitoring, which is coordinated by Dr Jéssica Ares Blanco. The main objective of this new study is: to establish the risk of mortality in the Spanish adult population with diagnosed diabetes, non-diagnosed diabetes and prediabetes. Asturias Study 2016.

As a result of collaborative work with Dr Fernández-Real, from Hospital Josep Trueta in Girona, we have been able to expand the basic version of these studies to include the determination of adiponectin and irisin levels, etc.

To date, this line of research has resulted in the production of a PhD thesis and several high-impact publications. These results have been communicated to our colleagues in primary care, with whom we have developed early diagnosis and prevention strategies for at-risk patients which are currently in use and subject to continuous evaluation. In light of these results, the health authorities have asked us to coordinate the current Key Interdisciplinary Care Programme for type 2 diabetes in Asturias.

Epidemiology of Diabetes and other Cardiovascular Risk Factors in the Spanish Population

In 2006, thanks to our experience in epidemiological research in Asturias and as members of the Sociedad Española de Diabetes (Epidemiological Group of the Spanish Diabetes Society, SED) we were asked to join the Managing Committee of the “Di@bet.es” Study (on the prevalence diabetes mellitus in Spain) at the beginning of the project. We are part of the group that designed, developed, launched and completed the Di@bet.es study, initially with support from SED itself and, since 2008, under the umbrella of the then newly-created CIBERDEM (Network Centre for Biomedical Research: Diabetes and Associated Metabolic Diseases). While the study was being conducted, we were the group responsible for carrying out fieldwork (completing interviews and physical examinations of the selected individuals, collecting blood samples and forwarding them to the central study base) for the node in northern Spain. After its launch, the Di@bet.es study came to be one of CIBERDEM’s key projects.

From that point onwards, we have conducted all of our research in close and fruitful collaboration with CIBERDEM members, as evidenced by the many publications produced and the fact that the last two research projects we were awarded (PI11/02795 are PI14/00970) were collaborative, the other groups (led by Dr Luis Castaño, Dr Gemma Rojo and Dr JF Chavez) being CIBERDEM members: the only group from outside CIBERDEM was our own.

In the first of these projects, we studied epigenetic mechanisms in the development of diabetes by analysing the global DNA methylation profiles of omental fat in obese individuals with and without DM2 and in non-obese control subjects. The results showed significant differences in methylation between the obese individuals and healthy control subjects at many CpG sites. Within the obese group, we identified several CpG sites that hypermethylate in individuals with TD2. These results can help improve our knowledge of the possible molecular causes and physiological consequences of this pathology, as well as the possible contribution of obesity surgery to the modification of these global DNA methylation patterns. Production of the results for this research is currently in the final stages.

The second project (PI14/00970) has two clear objectives:

  1. Firstly, this is the project within the Di@bet.es Study whose purpose is to establish the incidence of diabetes, determining the main associated risk factors and confirming that diet and a sedentary lifestyle are the most relevant factors . To do so, we have divided the fieldwork between the four groups within the collaborative project and our group is again responsible for the northern Spanish node.
  2. Secondly, we intend to extend the clinical applicability of the results obtained by our group’s global DNA methylation (methylome) profiling study of tissue samples associated with insulin resistance. This is an opportunity to develop simple, low-cost diagnosis and progression strategies that are specific to this pathology, with the additional benefit of developing personalised medicine and improved planning of how resources are allocated to care and prevention for this pathology.

All work in this line of research is performed in close partnership with our colleagues in IUOPA’s Cancer Epigenetics Unit (led by Dr Mario Fernández Fraga), which is another ISPA research group. Dr Fernández-Fraga is a world-leading researcher in the field of epigenetics and plays a particularly important role in this part of the project.

Epidemiology of Hydocarbon Metabolism Disorders in the Population Suffering from Cardiological Pathologies

In 2005, a new colleague from HUCA’s Cardiology Department joined the group (Dr Jesús María de la Hera) and, thanks to a grant from the Sociedad Española de la Cardiología (Spanish Cardiology Society), we launched a third line of research focused on the epidemiology of hydrocarbon metabolism disorders and their repercussion on the cardiovascular system.

We studied 580 consecutive patients who underwent a percutaneous coronary intervention. This involved performing a complete analysis, including of oral glucose tolerance and glycosylated haemoglobin for all patients without known diabetes (n=338). It was observed that the prevalence of diabetes in this population is very high (45%), of which 35% were hidden diabetics. We subsequently carried out a non-randomised observational study. We analysed the impact of intensive intervention by a multidisciplinary group on the patients in our health district without known diabetes and this was compared with the remaining subjects: a control group cared for by their assigned doctors. Finally, after an average follow-up period of 3.13 years, another oral glucose tolerance test was performed, which has shown us that the real incidence of diabetes in this coronary-patient population is 43.6 new cases per thousand people and per year, increasing to 70.5 if starting from a prediabetic state. Another risk model was also created, which enabled us to locate those patients at most risk of developing new diabetes in the follow-up period.

This line of research is still active, with work currently focused on the prospective follow-up of patients.

As a result of collaboration with Dr Fernández-Real at Hospital Josep Trueta in Girona, we have been able to expand the basic version of this study to include patients with cardiovascular disease who are correctly classified in terms of their hydrocarbon metabolism.

This line of research has resulted in the production of a PhD thesis and several publications in high-impact journals. It has also raised awareness in HUCA’s Cardiology Department of carbohydrate metabolism in its patients with cardiovascular disease, promoting compliance with the European Clinical Practice Guidelines and establishing local protocols with regular reviews.

Hyperglycaemia and Platelet Aggregation

We have been recently initiating another line of research on this group of patients with cardiovascular disease. “The acute effect of hyperglycaemia on platelet aggregation in anti-aggregation patients: the bas es for more powerful treatment in response to stress hyperglycaemia in acute coronary syndrome (ACS)”. Our working hypothesis is that more powerful anti-aggregation treatment could be effective in decreasing early cardiovascular events in patients with hyperglycaemia . Through a laboratory study, we aim to establish the bases upon which to predicate a late trial in this clinical context. The aim is to show that, in stable coronary patients not known to have DM and undergoing treatment with acetylsalicylic acid and clopidogrel, acute hyperglycaemia (caused by the oral glucose tolerance test – OGTT ) can create increased resistance to platelet anti-aggregation.

Patients who have had an ACS and do not have known diabetes mellitus will be selected, an OGTT will be performed on them, then their metabolic response to the carbohydrates and their platelet function will be examined.

Umbilical Cord Blood Stem Cells for Treating Type 1 Diabetes Mellitus

In 2012, we established this groundbreaking new line of research, in collaboration with HUCA’s Transplants, Cell Therapy and Regenerative Medicine Unit (Dr Jesús Otero and Dr Marcos López Basterrechea) and Immunology Department (Professor Carlos Larrea and Dr Beatriz Suarez), as well as Dr Yong Zhao from Hackensack University. This line of research has resulted in one publication and several presentations in the “14th International Congress. Immunology of Diabetes Society“ held in Munich (Germany) and the “American Diabetes Association (ADA) 75th Scientific Sessions 2015” held in Boston (US).

Having performed what we might term a “proof of concept” test, in which we treated 15 type 1diabetes mellitus patients in our centre and observed the safety of cell therapy, as well as the immunomodulation it caused, the next stage will be a randomised clinical trial on a recently-diagnosed group of type 1 diabetes mellitus patients, who will be treated with umbilical cord blood stem cells, and another group who will not, monitoring them over time to gain an accurate picture of efficacy.

Given this trial’s potential to produce important results and its significant logistical requirements, we believe that it should be conducted with the support of CIBERDEM and will submit the project for consideration in coming funding rounds.

Iodine Nutrition in the Asturian Population

We have carried out a range of studies on iodine nutrition and goitre epidemiology in Asturian school-aged subjects since the 1980s. As part of a Fundación Universidad de Oviedo project (FUO EM-122-09), we conducted a “study of the current situation regarding iodine nutrition in Asturias” from 2009 to 2010, the results of which are about to be published in Dr Maria Riestra’s PhD thesis, supervised by Drs Edelmiro Menéndez Torre and Elías Delgado Álvarez in the Department of Medicine of the Universidad de Oviedo.

Screening for Thyroid Dysfunction in Pregnant Women in the Oviedo Health District

In collaboration with the Obstetrics Department, thyroid dysfunction screening and an autoimmunity study have been conducted on all pregnant women in the Oviedo health district. The results have been the subject of several publications, as well as the PhD thesis presented by Marta Diéguez Felechosa in the Universidad de Oviedo Department of Medicine and supervised by Drs Edelmiro Menéndez Torre and Elías Delgado Álvarez.

As an extension of this study, we detected maternal hypothyroxinaemia of unknown origin, which we are investigating in collaboration with the Molecular Thyroid Laboratory of INGEMM (Medical and Molecular Genetics Institute) in Madrid, as well as its possible relationship to genetic mutations in the enzymes involved in iodine transport and organification in the thyroid.

Microbiota and Metabolism

Comparison of the intestinal microbiota of women with gestational diabetes to that of healthy pregnant women, and its possible impact on microbiota establishment in the newborn

This is a line of research that we hope to establish shortly. We have submitted it for evaluation in the 2017 basic research funding round of the Sociedad Española de Diabetes and will perform the study in collaboration with colleagues from CSIC’s Instituto de Productos Lácteos de Asturias (IPLA-CSIC).

Modification of the intestinal microbiota through dietary changes that confer cardio-metabolic benefits: The Modimicrob Project

The Modimicrob project will be conducted in collaboration with IPLA-CSIC and the Universidad de Oviedo. It aims to determine the appropriate conditions for modulating the metabolic activity of target microbial groups in the intestinal microbiota through combinations of standard dietary components and eventually incorporating probiotics to correct alterations in microbiota functionality in obese individuals.

First, the population under study will be defined on the basis of anthropometric, analytical, dietary habit and intestinal microbiota parameters through a pilot, cross-sectional, observational study comparing obese individuals to normal-weight, normoglycaemic individuals, among patients who visit the HUCA.

Once the targets for intervention in the intestinal microbiota of the selected population have been identified, we will conduct an in vitro evaluation of the impact on the functionality of the target microorganisms made by combinations of carbohydrates and proteins (or peptides / amino acids) of variable composition and structure present in the standard diet, some enteral formulas that are in use, as well as probiotics and polyphenols. We will consider, a priori, two main targets in the intestinal microbiota: the Bacteroides genus (the primary propionate producer) and the Faecalibacterium prausnitzii species (a butyrate producer). The following will be determined both in isolated microbial cultures and faecal cultures: production of short-chain fatty acids (SCFAs); consumption/production of amino acids; levels of bacterial gene expression related to SCFA production, and the effect of the HT29 intestinal cell line upon physiological and genetic parameters.

Finally, a diet will be designed on the basis of the results from the microbial and faecal cultures, whose efficacy for restoring intestinal microbiota functionality, analytical parameters and microbiota-host interaction will be tested against a standard diet in a pilot intervention study of patients belonging to the obese population under study.

Epigenetics and Thyroid Cancer

The results described in our publication in the Journal of Clinical Endocrinology and Metabolism (PMID:23666970), where we described the aberrant methylation patterns associated with each thyroid tumour subtype, will be used as a starting point for identifying which epigenetic changes associated with methylation may be involved in the development of follicular thyroid carcinomas, and whether these may be partly responsible for the evolution of follicular thyroid adenomas into follicular carcinomas.

To extend this research, and for the purpose of improving the diagnosis and monitoring tools for this pathology in our Endocrinology Department, we aim to identify another epigenetic marker – microRNAs (miRNA) – in FNAB (fine needle aspiration biopsies) and in blood, some of which may be found at higher or lower levels in follicular thyroid tumours in comparison to follicular adenomas and healthy control subjects. These may be used as treatment criteria when cytologies on benign thyroid pathologies produce indefinite results. These results may enable personalised treatment to be developed for patients with suspected follicular thyroid carcinomas.

 

In summary, within the context of a clinical hospital setting, we have been able to establish these lines of research thanks to the joint efforts of clinical (endocrinologists, cardiologists) and basic research (Epigenetics Unit) colleagues, as well as collaboration with other groups (the Transplant, Cell Therapy and Regenerative Medicine Unit and the Immunology Department).

The Di@bet.es Study merits special mention. This Spanish study demonstrates the power of over 20 research groups working collaboratively towards the same objective, under the leadership of Doctors Ramón Gomis and Federico Soriguer. We are very proud of having been part of this project from the outset. It has given us the opportunity to work very closely with prestigious, well-consolidated research groups, all of which belong to CIBERDEM.

All of this work has been completed while in an unstable situation: with significant effort, we have now gained funding for all projects, but the greatest challenge is securing the resources to engage the laboratory staff needed to conduct these projects. We are confident that gaining consolidated group status within ISPA will enable us to improve our infrastructure and productivity.

  1. Epidemiology of type 2 diabetes mellitus:
    1. “ASTURIAS Study”
    2. “Di@bet.es Incidence Study”
    3. Population with cardiological pathologies
  2. Studying the usefulness of epigenetics in the development of precision diagnosis strategies for endocrine pathologies:
    1. type 1 and 2 diabetes mellitus.
    2. Thyroid cancer
  3. Searching for the mechanism of action by which glycosurics create the cardiovascular benefit demonstrated in several clinical studies, through: imaging techniques, biomarkers, etc.
  4. Studying the alterations in the microbiota suffered by patients with endocrine diseases and the appropriate conditions to modulate/correct this, through standard dietary components and eventually incorporating probiotics, for patients with:
    1. Obesity
    2. Gestational diabetes
    3. Autoimmune thyroid disease
  5. Continuing with the prevention of iodine deficiency in Asturias: a line of research which began in 1982 and, in addition to ensuring the correct nutritional intake of iodine in the general population and pregnant women, has generated four PhD theses and a large number of publications, making the group a national leader in this area. In support of this research, a screening programme for thyroid dysfunction in pregnant women in the Oviedo health district has been running for five years, on an ongoing basis.
  • Avogaro A, Delgado E, Lingvay I. When Metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. Diabetes Metab Res Rev. 2018 Jan 10
  • Rodriguez-Rodero S, Menendez-Torre E, Fernandez-Bayon G, Morales-Sanchez P, Sanz L, Turienzo E, et al. Altered intragenic DNA methylation of HOOK2 gene in adipose tissue from individuals with obesity and type 2 diabetes. PLoS One. 2017;12(12):e0189153.
  • Riestra Fernandez M, Menendez Torre E, Diaz Cadorniga F, Fernandez Fernandez JC, Delgado Alvarez E. Iodine nutritional status in Asturian schoolchildren. Endocrinol Diabetes Nutr. 2017 Nov;64(9):491–7.
  • Zhao Y, Jiang Z, Delgado E, Li H, Zhou H, Hu W, et al. Platelet-Derived Mitochondria Display Embryonic Stem Cell Markers and Improve Pancreatic Islet β-cell Function in Humans. Stem Cells Transl Med. 2017 Aug;6(8):1684–97.
  • Prevalence, Diagnosis, Treatment, and Control of Hypertension in Spain. Results of the Di@bet.es Study. Rev Esp Cardiol (Engl Ed). 2016 Mar 12. pii: S1885-5857(16)00050-5. doi: 10.1016/j.rec.2015.11.034. [Epub ahead of print] English, Spanish.
  • Moreno M, Moreno-Navarrete JM, Serrano M, Ortega F, Delgado E, Sanchez-Ragnarsson C, et al. Circulating irisin levels are positively associated with metabolic risk factors in sedentary subjects. PLoS ONE. 2015;10(4):e0124100.
  • Delgado E, Perez-Basterrechea M, Suarez-Alvarez B, Zhou H, Revuelta EM, Garcia-Gala JM, et al. Modulation of Autoimmune T-Cell Memory by Stem Cell Educator Therapy: Phase 1/2 Clinical Trial. EBioMedicine [Internet]. 2015; 2(12): 2024-2036
  • Bellido V, Suarez L, Rodriguez MG, Sanchez C, Dieguez M, Riestra M, et al. Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes. Diabetes Care. 2015;38(12):2211-6.
  • Riobello C, Gómez J, Gil-Peña H, Tranche S, Reguero JR, Hera JM de la, Delgado E, Calvo D, Morís C, Santos F, Coto-Segura P, Iglesias S, Alonso B, Alvarez V, Coto E. {KCNQ1} gene variants in the risk for type 2 diabetes and impaired renal function in the Spanish Renastur cohort. Mol Cell Endocrinol. 2016;427:86-91
  • Ortega FJ, Agüera Z, Sabater M, Moreno-Navarrete JM, Alonso-Ledesma I, Xifra G, Botas P, Delgado E, Jimenez-Murcia S, Fernández-García JC, Tinahones FJ, Baños RM, Botella C, de la Torre R, Frühbeck G, Rodrigüez A, Estivill X, Casanueva F, Ricart W, Fernández-Aranda F, Fernández-Real JM. Genetic variations of the bitter taste receptor TAS2R38 are associated with obesity and impact on single immune traits. Mol Nutr Food Res 2016;60(7):1673-1683
  • de la Hera JM, García-Ruiz JM, Delgado E.Diabetes and Screening for Coronary Heart Disease: Where Should We Focus our Efforts?Rev Esp Cardiol (Engl Ed). octubre de 2015;68(10):830-3.
  • Ares J, Martin-Nieto A, Diaz-Naya L, Tarton T, Menendez-Prada T, Ragnarsson CS, et al. Gestational Diabetes Mellitus (GDM): Relationship Between Higher Cutoff Values for 100 g Oral Glucose Tolerance Test (OGTT) and Insulin Requirement During Pregnancy. Matern Child Health J. 2017 Jul;21(7):1488–92.
  • Valdés S, Maldonado-Araque C, García-Torres F, Goday A, Bosch-Comas A, Bordiú E, Calle-Pascual A, Carmena R, Casamitjana R, Castaño L, Castell C, Catalá M, Delgado E, Franch J, Gaztambide S, Girbés J, Gomis R, Gutiérrez G, López-Alba A, Martínez-Larrad M, Menéndez E, Mora-Peces I, Ortega E, Pascual-Manich G, Serrano-Rios M, Urrutia I, Vázquez JA, Vendrell J, Soriguer F, Rojo-Martínez G. Ambient temperature and prevalence of obesity in the Spanish population. Di@bet.es study.Obesity. 2014;22(11):2328-2332
  • Riestra Fernández M, Menendez Torre E, Diaz Cadorniga F, Fernandez Fernandez JC, Delgado Alvarez E. Iodine nutritional status in Asturian schoolchildren. Endocrinol Diabetes Nutr. 2017 Nov;64(9):491–7.
  • Rodriguez-Rodero S, Delgado-Alvarez E, Diaz-Naya L, Martin Nieto A, Menendez Torre E. Epigenetic modulators of thyroid cancer. Endocrinol Diabetes Nutr. 2017 Jan;64(1):44–56.
  • Rodriguez-Rodero S, Delgado-Alvarez E, Fernandez AF, Fernandez-Morera JL, Menendez-Torre E, Fraga MF. Epigenetic alterations in endocrine-related cancer. Endocr Relat Cancer. agosto de 2014;21(4):R319-30
  • Menéndez Torre E, Delgado Álvarez E, Rabal Artal A, Suárez Gutiérrez L, Rodríguez Caballero MG, Ares Blanco J, Díaz Naya L, Fernandez Fernandez JC. Nutrición de yodo en mujeres embarazadas del área de Oviedo. ¿Es necesaria la suplementación con yodo? Endocrinología y Nutrición . 2014; 61(8):404-409.
  • Dieguez M, Herrero A, Avello N, Suarez P, Delgado E, Menendez E. Prevalence of thyroid dysfunction in women in early pregnancy: does it increase with maternal age? Clin Endocrinol (Oxf). 8 de diciembre de 2014
  • Delgado E. Unmet needs in the treatment of type 2 diabetes. Med Clin (Barc). 2014;143 ( 2):41-3.
  • de la Hera Galarza JM, García-Ruiz JM, Delgado Álvarez E, Ferreiro JL. Tiempo de evolución de la diabetes mellitus como factor determinante en la modificación de la reactividad plaquetaria. Revista Española de Cardiología. marzo de 2014;67(3):2

Identification of epigenetic markers associated with the development of type 2 diabetes mellitus in the Spanish population

  • Principal Investigator: Elías Delgado Álvarez
  • Funding Body: Instituto de la salud Carlos III
  • Reference Number: PI14/00970
  • Amount: €93,170

Genetic and epigenetic factors in the development of type 2 diabetes mellitus in the Spanish population

  • Principal Investigator: Elías Delgado Álvarez
  • Funding Body: Instituto de la salud Carlos III
  • Reference Number: PI11/02795
  • Amount: €50,517.50

Epigenetic profile of morbid obesity in tissues associated with the development of type 2 diabetes mellitus

  • Principal Investigator: Edelmiro Menéndez Torre
  • Funding Body: Fundación Mutua Madrileña
  • Amount: €25,000
Supervisors Title PhD Student Organisation Date of Viva
Elías Delgado Álvarez
Edelmiro Luis Menéndez Torre
The current situation regarding nutritional intake of iodine in Asturias after 28 years of iodine prophylaxis in salt. María Riestra Fernández Universidad de Oviedo 26/5/2017
María Fernanda Lorenzo Gómez
Bárbara Padilla Fernández
The influence of antidiabetic treatment in the response to erectile dysfunction treatment Lorena Suárez Gutiérrez Universidad de Salamanca 28/07/2017
Elías Delgado Álvarez
Edelmiro Menéndez Torre
The prevalence of thyroid dysfunction in pregnant women in Asturian health district IV Marta Diéguez Felechosa Universidad de Oviedo 14/07/2015
Elías Delgado Álvarez
Alfonso López Muñiz
The prevalence of hydrocarbon metabolism disorders in patients who undergo percutaneous coronary interventions. Jesús María de la Hera Galarza Universidad de Oviedo 11/12/2013

A 24-Week, Multicentre, Randomised, Open-Label, 2-Arm Parallel-group Study Evaluating the Efficacy and Safety of Patient- Versus Physician-managed Titration of Insulin Glargine U300 in Type 2 Diabetes Mellitus

  • Principal Investigator: Elías Delgado
  • Code: LPS 14409
  • Sponsor: Sanofi
  • Started in May 2016 and completed in December 2017. Currently in post-treatment review

A Phase 3, Randomised, Double-Blind, Active-Controlled Study to Evaluate the Effects of Bexagliflozin Versus Glimepiride in Subjects with Type 2 Diabetes Mellitus who have Inadequate Glycaemic Control by Metformin

  • Principal Investigator: Elías Delgado
  • Code: THR-1442-C480
  • Sponsor: Theracos
  • Started in January 2017 with a duration of two years (98 weeks of treatment)

Dapagliflozin Effect on Cardiovascular Events. DECLARE-TIMI-35

  • Principal Investigator: Elías Delgado
  • Code: D1693-C-0001
  • Sponsor: AstraZeneca
  • Started in 2012. Expected to be completed in 2019

A European Observational Study of Pasireotide LAR in Patients With Acromegaly – Acronis Study

  • Principal Investigator: Edelmiro Menéndez
  • Code: CSOM230CIC05
  • Sponsor: Novartis

European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib 300 mg in Thyroid Cancer

  • Principal Investigator: Edelmiro Menéndez
  • Code: D4200C00104
  • Sponsor: AstraZeneca

Radioactive Iodine Refractory Asymptomatic Patients in Differentiated Thyroid Cancer

  • Principal Investigator: Cecilia Sánchez
  • Code: BAY-SOR-2014-01
  • Sponsor: Bayer

Subcutaneous Versus Intravenous Basal Insulin in Non-Critical Hospitalised Diabetic Patients Receiving Total Parenteral Nutrition.

  • Principal Investigator: Laura Manjón
  • Code: FPS-INSUPAR-2015-01
  • Sponsor: Fundación Pública Andaluza Progreso y Salud (Andalusian Public Progress and Health Foundation)